Journal article
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Abstract
BACKGROUND: Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
METHODS: We randomly assigned previously untreated patients with confirmed AML who were ineligible for standard induction therapy because of coexisting conditions, because they were 75 years of age or older, or both to …
Authors
DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P
Journal
New England Journal of Medicine, Vol. 383, No. 7, pp. 617–629
Publisher
Massachusetts Medical Society
Publication Date
August 13, 2020
DOI
10.1056/nejmoa2012971
ISSN
0028-4793
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAzacitidineBridged Bicyclo Compounds, HeterocyclicDouble-Blind MethodFemaleFollow-Up StudiesHumansIntention to Treat AnalysisKaplan-Meier EstimateLeukemia, Myeloid, AcuteLeukopeniaMaleMiddle AgedPneumoniaRecurrenceRemission InductionSulfonamidesThrombocytopenia